SELLAS nearly triples as its leukemia vaccine extends survival
Why is SELLAS stock up today?
SELLAS said its Phase 3 REGAL trial of galinpepimut-S, a vaccine meant to keep acute myeloid leukemia from returning, met its main goal: patients lived a median 24.0 months, against 14.7 months on the doctors' choice of other treatment. The shares closed up about 156% at $19.15; these are company-reported topline results, the detailed analyses are still pending, and SELLAS has not yet applied for FDA approval. After the close, it filed to sell $150 million of new stock.
What it means
- What changed
- SELLAS reported a survival benefit for GPS in a small, randomized, open-label Phase 3 trial.
- What hasn't changed
- SELLAS has not submitted a BLA for GPS or received marketing approval, the detailed results are unpublished, and it has no product sales.
- Next · First half of 2027 (company plan)
- SELLAS's application for FDA approval of galinpepimut-S, after it meets the agency.
- Move
- ▲ 156.4%
- Price
- $7.47 → $19.15
- Value gained
- ~$2.4B
- Median survival
- 24.0 vs 14.7 months
- Hazard ratio
- 0.59 (p = 0.035)
- Cash
- $134.7M (Sep 30)
Prices: official close, CNBC, Yahoo Finance, Nov 17, 2026 · Company data: 10-Q, Sep 30, 2026 · What these numbers mean
Closing prices on Nov 17, 2026, from Yahoo Finance and CNBC. The previous close is the official Nov 16 close. Value gained is our estimate, using the 203,859,151 common shares outstanding on Nov 11, 2026 (10-Q cover).
Snapshot at the Nov 17, 2026 close
- Market value
- $3.9B
- Cash and investments
- $135M
- Enterprise value
- $3.8B
- Cash use per quarter
- $7M
- Price/sales
- n/m
- P/E
- n/m
Our calculation from the company's filings (latest: 10-Q for the quarter to Sep 30, 2026, filed Nov 12, 2026); not investment advice. Revenue, earnings and cash flow: 12 months to Sep 30, 2026. Price $19.15 (official close, CNBC, Yahoo Finance); 203.9 million shares (common shares on the cover page of the 10-Q filed Nov 12, 2026). n/m = not meaningful (e.g. negative earnings).
Price data
| Date | Close |
|---|---|
| Nov 17, 2025 | $1.41 |
| Nov 18, 2025 | $1.59 |
| Nov 19, 2025 | $1.52 |
| Nov 20, 2025 | $1.46 |
| Nov 21, 2025 | $1.53 |
| Nov 24, 2025 | $1.55 |
| Nov 25, 2025 | $1.44 |
| Nov 26, 2025 | $1.46 |
| Nov 28, 2025 | $1.62 |
| Dec 1, 2025 | $1.50 |
| Dec 2, 2025 | $1.39 |
| Dec 3, 2025 | $1.54 |
| Dec 4, 2025 | $1.74 |
| Dec 5, 2025 | $1.74 |
| Dec 8, 2025 | $1.82 |
| Dec 9, 2025 | $1.90 |
| Dec 10, 2025 | $1.96 |
| Dec 11, 2025 | $2.01 |
| Dec 12, 2025 | $2.03 |
| Dec 15, 2025 | $2.04 |
| Dec 16, 2025 | $2.20 |
| Dec 17, 2025 | $2.11 |
| Dec 18, 2025 | $2.34 |
| Dec 19, 2025 | $2.36 |
| Dec 22, 2025 | $2.64 |
| Dec 23, 2025 | $2.77 |
| Dec 24, 2025 | $2.84 |
| Dec 26, 2025 | $2.87 |
| Dec 29, 2025 | $3.35 |
| Dec 30, 2025 | $3.31 |
| Dec 31, 2025 | $3.77 |
| Jan 2, 2026 | $4.35 |
| Jan 5, 2026 | $5.00 |
| Jan 6, 2026 | $4.10 |
| Jan 7, 2026 | $4.04 |
| Jan 8, 2026 | $3.86 |
| Jan 9, 2026 | $3.46 |
| Jan 12, 2026 | $4.11 |
| Jan 13, 2026 | $4.15 |
| Jan 14, 2026 | $4.11 |
| Jan 15, 2026 | $3.84 |
| Jan 16, 2026 | $3.98 |
| Jan 20, 2026 | $4.32 |
| Jan 21, 2026 | $4.58 |
| Jan 22, 2026 | $4.51 |
| Jan 23, 2026 | $4.26 |
| Jan 26, 2026 | $4.30 |
| Jan 27, 2026 | $4.40 |
| Jan 28, 2026 | $3.97 |
| Jan 29, 2026 | $3.89 |
| Jan 30, 2026 | $3.77 |
| Feb 2, 2026 | $3.97 |
| Feb 3, 2026 | $4.16 |
| Feb 4, 2026 | $3.82 |
| Feb 5, 2026 | $3.53 |
| Feb 6, 2026 | $3.73 |
| Feb 9, 2026 | $3.81 |
| Feb 10, 2026 | $3.76 |
| Feb 11, 2026 | $3.67 |
| Feb 12, 2026 | $3.55 |
| Feb 13, 2026 | $3.59 |
| Feb 17, 2026 | $3.66 |
| Feb 18, 2026 | $3.79 |
| Feb 19, 2026 | $4.04 |
| Feb 20, 2026 | $4.15 |
| Feb 23, 2026 | $4.50 |
| Feb 24, 2026 | $4.74 |
| Feb 25, 2026 | $4.55 |
| Feb 26, 2026 | $4.92 |
| Feb 27, 2026 | $4.93 |
| Mar 2, 2026 | $5.05 |
| Mar 3, 2026 | $5.31 |
| Mar 4, 2026 | $5.54 |
| Mar 5, 2026 | $5.28 |
| Mar 6, 2026 | $5.53 |
| Mar 9, 2026 | $5.96 |
| Mar 10, 2026 | $5.82 |
| Mar 11, 2026 | $5.48 |
| Mar 12, 2026 | $5.03 |
| Mar 13, 2026 | $5.37 |
| Mar 16, 2026 | $5.36 |
| Mar 17, 2026 | $5.04 |
| Mar 18, 2026 | $4.95 |
| Mar 19, 2026 | $5.20 |
| Mar 20, 2026 | $4.76 |
| Mar 23, 2026 | $5.48 |
| Mar 24, 2026 | $5.00 |
| Mar 25, 2026 | $5.30 |
| Mar 26, 2026 | $4.95 |
| Mar 27, 2026 | $4.37 |
| Mar 30, 2026 | $4.01 |
| Mar 31, 2026 | $4.23 |
| Apr 1, 2026 | $4.21 |
| Apr 2, 2026 | $4.13 |
| Apr 6, 2026 | $4.53 |
| Apr 7, 2026 | $4.51 |
| Apr 8, 2026 | $4.86 |
| Apr 9, 2026 | $5.05 |
| Apr 10, 2026 | $4.76 |
| Apr 13, 2026 | $4.76 |
| Apr 14, 2026 | $4.86 |
| Apr 15, 2026 | $4.91 |
| Apr 16, 2026 | $4.93 |
| Apr 17, 2026 | $5.22 |
| Apr 20, 2026 | $4.99 |
| Apr 21, 2026 | $5.03 |
| Apr 22, 2026 | $4.78 |
| Apr 23, 2026 | $4.64 |
| Apr 24, 2026 | $4.46 |
| Apr 27, 2026 | $4.88 |
| Apr 28, 2026 | $4.88 |
| Apr 29, 2026 | $4.67 |
| Apr 30, 2026 | $4.95 |
| May 1, 2026 | $4.93 |
| May 4, 2026 | $5.02 |
| May 5, 2026 | $4.87 |
| May 6, 2026 | $5.15 |
| May 7, 2026 | $4.93 |
| May 8, 2026 | $5.01 |
| May 11, 2026 | $5.25 |
| May 12, 2026 | $5.22 |
| May 13, 2026 | $6.53 |
| May 14, 2026 | $7.42 |
| May 15, 2026 | $7.08 |
| May 18, 2026 | $7.29 |
| May 19, 2026 | $7.59 |
| May 20, 2026 | $8.97 |
| May 21, 2026 | $7.56 |
| May 22, 2026 | $7.78 |
| May 26, 2026 | $8.12 |
| May 27, 2026 | $8.58 |
| May 28, 2026 | $9.18 |
| May 29, 2026 | $9.31 |
| Jun 1, 2026 | $9.07 |
| Jun 2, 2026 | $8.33 |
| Jun 3, 2026 | $8.19 |
| Jun 4, 2026 | $9.04 |
| Jun 5, 2026 | $8.23 |
| Jun 8, 2026 | $7.98 |
| Jun 9, 2026 | $7.68 |
| Jun 10, 2026 | $7.15 |
| Jun 11, 2026 | $7.75 |
| Jun 12, 2026 | $7.83 |
| Jun 15, 2026 | $7.73 |
| Jun 16, 2026 | $7.53 |
| Jun 17, 2026 | $7.76 |
| Jun 18, 2026 | $8.05 |
| Jun 22, 2026 | $8.53 |
| Jun 23, 2026 | $9.07 |
| Jun 24, 2026 | $9.17 |
| Jun 25, 2026 | $10.53 |
| Jun 26, 2026 | $12.39 |
| Jun 29, 2026 | $15.45 |
| Jun 30, 2026 | $14.76 |
| Jul 1, 2026 | $13.27 |
| Jul 2, 2026 | $14.98 |
| Jul 6, 2026 | $13.94 |
| Jul 7, 2026 | $13.50 |
| Jul 8, 2026 | $13.76 |
| Jul 9, 2026 | $13.51 |
| Jul 10, 2026 | $12.76 |
| Jul 13, 2026 | $12.62 |
| Jul 14, 2026 | $13.39 |
| Jul 15, 2026 | $12.79 |
| Jul 16, 2026 | $11.75 |
| Jul 17, 2026 | $13.19 |
| Jul 20, 2026 | $12.48 |
| Jul 21, 2026 | $12.90 |
| Jul 22, 2026 | $12.08 |
| Jul 23, 2026 | $12.34 |
| Jul 24, 2026 | $11.32 |
| Jul 27, 2026 | $10.84 |
| Jul 28, 2026 | $10.09 |
| Jul 29, 2026 | $10.10 |
| Jul 30, 2026 | $10.29 |
| Jul 31, 2026 | $10.01 |
| Aug 3, 2026 | $11.22 |
| Aug 4, 2026 | $11.81 |
| Aug 5, 2026 | $11.86 |
| Aug 6, 2026 | $11.70 |
| Aug 7, 2026 | $12.01 |
| Aug 10, 2026 | $11.04 |
| Aug 11, 2026 | $11.05 |
| Aug 12, 2026 | $11.77 |
| Aug 13, 2026 | $12.36 |
| Aug 14, 2026 | $12.78 |
| Aug 17, 2026 | $13.00 |
| Aug 18, 2026 | $13.10 |
| Aug 19, 2026 | $13.85 |
| Aug 20, 2026 | $13.40 |
| Aug 21, 2026 | $15.46 |
| Aug 24, 2026 | $14.33 |
| Aug 25, 2026 | $14.09 |
| Aug 26, 2026 | $13.73 |
| Aug 27, 2026 | $15.21 |
| Aug 28, 2026 | $13.21 |
| Aug 31, 2026 | $13.34 |
| Sep 1, 2026 | $13.22 |
| Sep 2, 2026 | $14.16 |
| Sep 3, 2026 | $13.70 |
| Sep 4, 2026 | $13.86 |
| Sep 8, 2026 | $13.96 |
| Sep 9, 2026 | $13.95 |
| Sep 10, 2026 | $13.49 |
| Sep 11, 2026 | $11.55 |
| Sep 14, 2026 | $11.73 |
| Sep 15, 2026 | $11.29 |
| Sep 16, 2026 | $11.66 |
| Sep 17, 2026 | $11.53 |
| Sep 18, 2026 | $11.49 |
| Sep 21, 2026 | $11.37 |
| Sep 22, 2026 | $12.02 |
| Sep 23, 2026 | $11.52 |
| Sep 24, 2026 | $11.98 |
| Sep 25, 2026 | $11.61 |
| Sep 28, 2026 | $11.59 |
| Sep 29, 2026 | $11.51 |
| Sep 30, 2026 | $12.31 |
| Oct 1, 2026 | $11.33 |
| Oct 2, 2026 | $11.74 |
| Oct 5, 2026 | $11.63 |
| Oct 6, 2026 | $11.34 |
| Oct 7, 2026 | $11.31 |
| Oct 8, 2026 | $11.26 |
| Oct 9, 2026 | $11.65 |
| Oct 12, 2026 | $11.93 |
| Oct 13, 2026 | $12.41 |
| Oct 14, 2026 | $11.88 |
| Oct 15, 2026 | $11.34 |
| Oct 16, 2026 | $9.98 |
| Oct 19, 2026 | $10.49 |
| Oct 20, 2026 | $11.98 |
| Oct 21, 2026 | $12.14 |
| Oct 22, 2026 | $11.35 |
| Oct 23, 2026 | $11.54 |
| Oct 26, 2026 | $11.34 |
| Oct 27, 2026 | $12.17 |
| Oct 28, 2026 | $10.38 |
| Oct 29, 2026 | $10.16 |
| Oct 30, 2026 | $9.68 |
| Nov 2, 2026 | $8.55 |
| Nov 3, 2026 | $8.87 |
| Nov 4, 2026 | $9.14 |
| Nov 5, 2026 | $7.88 |
| Nov 6, 2026 | $8.42 |
| Nov 9, 2026 | $8.58 |
| Nov 10, 2026 | $8.37 |
| Nov 11, 2026 | $8.42 |
| Nov 12, 2026 | $8.03 |
| Nov 13, 2026 | $7.86 |
| Nov 16, 2026 | $7.47 |
SELLAS said its leukemia vaccine extended survival in the Phase 3 REGAL trial. These are company-reported topline results; the detailed analyses are still pending, and SELLAS has not submitted its application for FDA approval.
What happened
Before the open, SELLAS said REGAL, its Phase 3 trial of galinpepimut-S (GPS), met its primary goal of longer overall survival in acute myeloid leukemia (AML), a fast-growing blood cancer.
- The shares closed up about 156% at $19.15, from Monday’s $7.47 close, after opening at about $24 and trading as high as $24.89 (CNBC, Yahoo Finance). The SPDR S&P Biotech ETF (XBI) fell 0.4% (CNBC).
- Patients on GPS lived a median 24.0 months, against 14.7 months for patients given their doctors’ choice of other treatment. The hazard ratio was 0.59, which SELLAS describes as a 41% lower risk of death, with a two-sided p-value of 0.035.
- SELLAS said GPS was generally well tolerated, with treatment-related adverse events predominantly mild or moderate, most commonly injection-site reactions, and no new safety signals.
The jump reverses a slide. The shares rose from about $1 at the end of 2024 to $15.46 on Aug 21, 2026, then fell to Monday’s $7.47, including 15% on Oct 28, the day SELLAS said the trial had reached the 80 deaths that triggered this final analysis (our calculation from Yahoo Finance closes).
The result, in figures
SELLAS release (8-K Exhibit 99.1), Nov 17, 2026: “The REGAL trial met its primary endpoint of overall survival (OS), with GPS demonstrating a statistically significant and clinically meaningful improvement in OS compared with investigator’s choice of best available treatment (BAT).” Median OS 24.0 months on GPS against 14.7 months on BAT; hazard ratio 0.59; “a two-sided p=0.035”. The analysis followed “the pre-specified occurrence of 80 events (deaths)”. Chief executive Angelos Stergiou: the result “provides Phase 3 validation of our WT1-targeted immunotherapeutic technology”. Prices (CNBC, Yahoo Finance): $7.47 at the Nov 16 close; open about $24.0; high $24.89; low about $16.70; $19.15 at the Nov 17 close (+156.4%; Yahoo Finance and CNBC). XBI −0.4% and SPY −1.0% at the close (CNBC). Earlier closes (Yahoo Finance): $1.04 on Dec 31, 2024; $15.46 on Aug 21, 2026; $12.17 on Oct 27 and $10.38 on Oct 28, 2026 (−14.7%). Market value: 203,859,151 shares (Nov 11, 10-Q cover) × $19.15 = about $3.9 billion, up about $2.4 billion from $1.5 billion at Monday’s close (our calculation).
What the trial showed, and what it didn’t
REGAL studied a narrow group of patients: adults whose AML was in a second or later complete remission after salvage treatment, including those whose platelet counts had not fully recovered, and who were ineligible or unable to undergo an allogeneic stem cell transplant.
- SELLAS said 126 patients were randomized 1:1 to GPS on its own or their doctors’ choice of observation, a hypomethylating agent, venetoclax and/or low-dose cytarabine, including combinations. The trial was open-label, so patients and doctors knew the assigned treatment.
- The release does not give the control-treatment breakdown, confidence intervals for the survival estimates or hazard ratio, or detailed adverse-event rates. SELLAS said the two groups were balanced for the factors used to stratify patients and that few patients in either group went on to a transplant.
- The secondary goals, including leukemia-free survival and the immune response, are still being analysed. SELLAS said the full results will be presented at a major medical conference and submitted to a peer-reviewed journal; it did not give a date.
- At the January 2025 interim analysis, an independent monitoring committee recommended continuing the trial without changes. SELLAS said GPS cleared the predetermined futility criteria; this was not the final survival result.
What comes next
SELLAS plans to meet the FDA to discuss what it called “an accelerated filing strategy” and to prepare a Biologics License Application, its request for approval, for submission in the first half of 2027.
- No meeting date has been announced. SELLAS has not submitted the application or received approval. Its release cautions that the FDA may disagree with its interpretation of the results or its proposed filing and expedited-review strategy.
- Maxim analyst Jason McCarthy, who rates the shares Buy with a $30 price target, models GPS in AML from 2027 and SELLAS’s second drug, SLS009 (tambiciclib), in newly diagnosed AML from 2029, TipRanks reported.
Cash and the share count
SELLAS had $134.7 million of cash at Sept. 30 and expects it to fund planned operations for at least 12 months from its Nov 12 quarterly report. It lost $28.1 million in the first nine months of 2026 and has no product sales.
- After the close, SELLAS filed a preliminary prospectus to sell $150 million of new common stock through J.P. Morgan and TD Cowen, plus a 30-day option for the underwriters to buy $22.5 million more; the price had not been set. It said it plans to use the money for its operations, clinical development and costs related to potential commercialization. The prospectus says its separate $150 million ATM with TD Cowen, set up in March, remained fully available for sales after expiration or waiver of SELLAS’s lock-up period.
- Its share count has nearly tripled in under two years, mostly as investors exercised warrants: from 74.0 million at the end of 2024 to 203.9 million on Nov 11, 2026. Warrant exercises brought in $85.1 million in 2026’s first nine months, and warrants for 8.1 million more shares were outstanding at Sept. 30.
SELLAS's shares outstanding, 2020 to 2026 (millions)
The share count rose from 74.0 million at the end of 2024 to 203.5 million at Sept. 30, 2026, mostly through warrant exercises.
Show the data table
| Date | Shares outstanding (M) |
|---|---|
| End-2020 | 14.3 |
| End-2021 | 15.9 |
| End-2022 | 21.0 |
| End-2023 | 32.1 |
| End-2024 | 74.0 |
| End-2025 | 153.1 |
| Sep 30, 2026 | 203.5 |
Cash and shares, in figures
10-Q for the quarter to Sept. 30, 2026 (filed Nov 12): cash and cash equivalents “approximately $134.7 million”; “We expect that our cash and cash equivalents will be sufficient to fund our current planned operations for at least the next twelve months from the date of issuance of these financial statements, although we may pursue additional capital resources”. Net loss of $28.1 million and cash used in operations of $22.4 million in the first nine months. 2026 ATM: “aggregate gross proceeds of up to $150.0 million”; “We have not sold any shares of common stock pursuant to the 2026 ATM to date.” Warrant exercises: “approximately $85.1 million from the exercise of 50.4 million outstanding warrants at a weighted average exercise price of $1.69 per share” in the nine months. Reserved for issuance at Sept. 30: warrants 8,122 thousand; stock options 2,651 thousand; RSUs 3,310 thousand. Shares outstanding: 73,977,459 at Dec 31, 2024; 153,103,459 at Dec 31, 2025; 203,527,833 at Sept. 30, 2026; 203,859,151 on Nov 11, 2026 (cover). Shelf: automatic registration statement on Form S-3ASR, Mar 20, 2026. Preliminary prospectus supplement (Form 424B5, accepted 4:14 p.m. ET on Nov 17, “Subject to completion”): “$150,000,000 Common stock”; the underwriters’ option “to purchase up to an additional $22,500,000”; joint book-running managers J.P. Morgan and TD Cowen; the Sales Agreement for up to $150 million, “all of which remains available as of the date of this prospectus supplement”, for use “after the expiration or waiver of the lock-up period applicable to us”. About 325,000 warrants were exercised after Sept. 30 for about $0.5 million (10-Q).
What happened to others after jumps like this
We looked at 54 cases since 2015 in which a US-listed biotech jumped at least 75% in a day on positive late-stage trial news, found through dated news reports and checked against SEC filings. For the 31 that still have a price history, the median move from the jump-day close was slightly positive at each measured horizon through six months, between +1% and +6%, and about −10% after a year, when 17 of 28 were below their jump-day close; the range was wide, from a 95% loss to a 154% gain. Filings within 30 days show 37 of the 54 selling or agreeing to sell new stock outside at-the-market programs, one of them agreed before the readout; the filings typically came about three days after the jump, and the 34 offerings priced after it had a median price 4.6% below the jump-day close. Nineteen were later acquired, mostly at prices well above the jump-day close. The main limit: acquired and delisted companies drop out of the price data, which can push the medians either way by amounts we can’t measure.
| Company | Jump day | Day-1 move | Afterwards |
|---|---|---|---|
| Amarin (AMRN) | Sep 24, 2018 | +315% | +28% a year after the jump-day close; the FDA approved the wider heart-risk label in Dec 2019 |
| Cidara (CDTX) | Jun 23, 2025 | +114% | Priced a $350 million stock sale the next day at $44; Merck bought it for $221.50 a share in Jan 2026 |
| Vistagen (VTGN) | Aug 7, 2023 | +677% | −75% a year after the jump-day close; its next Phase 3 trial failed in Dec 2025 |
| Veru (VERU) | Apr 11, 2022 | +182% | −91% a year after the jump-day close; the FDA declined emergency use in Mar 2023 |
How we counted, in figures
Sample: US-listed biotechs with a one-day gain of 75% or more on positive late-stage trial results, including specified pivotal Phase 2 and efficacy-stop announcements, 2015 to November 2026, from named, dated news reports; 58 events found, 4 left out (an extension readout, an unverified close and two re-analyses), leaving 54 events at 52 companies. Returns run close to close from the jump-day close, over 5, 21, 63, 126 and 252 trading days, using split-adjusted Yahoo Finance prices; 31 events could be priced (30 at six months, 28 at a year). Medians: +4.0% after a week, +5.5% after a month, +0.8% after three months, +3.8% after six months and −9.6% after a year; at a year, 7 of 28 were down 50% or more and 5 of 28 up 50% or more, and 5 of 28 were at or below their price before the news. Filings within 30 days point to non-ATM cash equity transactions at 37 of 54 events: 35 offerings and two private placements, including one placement agreed before the readout. Completion was not checked for every deal. The median interval to the selected filing or notice date was about three calendar days. Among 34 post-jump priced offerings, the median price was 4.6% below the jump-day close. ATM sales are mostly not captured. Outcomes for all 54: 19 acquired (deal price above the jump-day close in 14 of 18 with both figures), 14 approved and still independent, 9 setbacks, 2 delisted or bankrupt, 8 pending, 2 other. Amarin: +314.7% to $12.40 on Sep 24, 2018 (TheStreet); +28.1% after 252 trading days. Cidara: +114% to $44.95 on Jun 23, 2025; $350 million offering priced Jun 24 at $44.00 (424B5); Merck’s $221.50 tender completed Jan 7, 2026. Vistagen: +677% to $13.05 on Aug 7, 2023; −75.3% after a year; PALISADE-3 topline Dec 17, 2025. Veru: +182.3% to $12.28 on Apr 11, 2022; −91.4% after a year; FDA update Mar 2, 2023. These are past cases; they don’t describe SELLAS’s prospects (our research and calculation).
The other view
Maxim analyst Jason McCarthy rates the shares Buy with a $30 price target and models galinpepimut-S in AML from 2027, TipRanks reported; it did not report a new note or target change today.
Source: TipRanks, Nov 17, 2026
What to watch next
- Not announced
- The pricing of SELLAS's $150 million share offering: the price per share and the number of new shares.
- Date not announced
- SELLAS's meeting with the FDA to discuss what it calls an accelerated filing strategy.
- Date not given
- Presentation of the detailed REGAL results at a major medical conference and submission to a peer-reviewed journal.
- First half of 2027 (company plan)
- The Biologics License Application, SELLAS's request for FDA approval.
Quick questions
What is galinpepimut-S?
An experimental cancer vaccine, also called GPS, that SELLAS licensed from Memorial Sloan Kettering Cancer Center. It is made of four protein fragments from WT1, a protein found on many leukemia cells, and is meant to train the immune system to attack leukemia cells left after treatment. It is not approved anywhere.
What is a hazard ratio of 0.59?
A hazard ratio compares the estimated risk of dying at a given point during follow-up among patients still alive. A ratio of 0.59 indicates an estimated 41% lower death hazard with GPS; it does not mean 41% fewer patients died. SELLAS reported a two-sided p-value of 0.035 and said the trial met its primary endpoint.
Has SELLAS raised money after the result?
SELLAS has proposed an offering; the preliminary filing does not establish that proceeds have been raised. After the close on Nov 17, SELLAS filed a preliminary prospectus to sell $150 million of new common stock in an underwritten offering led by J.P. Morgan and TD Cowen, with a 30-day option for the underwriters to buy $22.5 million more. The price and the number of shares had not been set. The prospectus says its separate $150 million at-the-market program with TD Cowen remained fully available for sales after expiration or waiver of SELLAS's lock-up period.
About SELLAS: Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)
+ 16 more
Accessed Nov 17, 2026: SELLAS: 2025 annual report (SEC Form 10-K) · SELLAS: 2023 annual report (SEC Form 10-K) · SELLAS: 2021 annual report (SEC Form 10-K) · SELLAS: REGAL trial reaches its 80th event (Oct 28, 2026) · SELLAS: positive outcome of the REGAL interim analysis (Jan 2025) · SELLAS: automatic shelf registration (SEC Form S-3ASR, Mar 20, 2026) · ClinicalTrials.gov: REGAL (NCT04229979) · TipRanks: Why SELLAS Life Sciences stock is skyrocketing over 200% today, and what this analyst sees next (Nov 17, 2026) · Amarin: REDUCE-IT topline results (SEC Form 8-K, Sep 24, 2018) · Amarin: 2020 Form 10-Q confirming the December 2019 cardiovascular label expansion · Cidara: $350 million offering prospectus (SEC Form 424B5, Jun 2025) · Merck: completion of the Cidara acquisition (Jan 2026) · Vistagen: PALISADE-3 Phase 3 topline results (Dec 17, 2025) · Veru: FDA update on its request for emergency use (Mar 2, 2023) · CNBC: SLS quote · Yahoo Finance: SLS prices
Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.